Would you consider nivolumab and ipilimumab as first line for pleural mesothelioma?

I found the overall survival benefit of Checkmate 743 presented at the WLCL presentation compelling. This is the most significant phase III data we have had and I was particularly encouraged by the sarcomatoid subset - traditionally much harder to treat - seeming to benefit at least the same if not ...